The ocular conjunctiva as a mucosal immunization route: a profile of the immune response to the model antigen tetanus toxoid

PLoS One. 2013 Apr 26;8(4):e60682. doi: 10.1371/journal.pone.0060682. Print 2013.

Abstract

Background: In a quest for a needle-free vaccine administration strategy, we evaluated the ocular conjunctiva as an alternative mucosal immunization route by profiling and comparing the local and systemic immune responses to the subcutaneous or conjunctival administration of tetanus toxoid (TTd), a model antigen.

Materials and methods: BALB/c and C57BL/6 mice were immunized either subcutaneously with TTd alone or via the conjunctiva with TTd alone, TTd mixed with 2% glycerol or TTd with merthiolate-inactivated whole-cell B. pertussis (wBP) as adjuvants. Mice were immunized on days 0, 7 and 14 via both routes, and an evaluation of the local and systemic immune responses was performed two weeks after the last immunization. Four weeks after the last immunization, the mice were challenged with a lethal dose (2 × LD50) of tetanus toxin.

Results: The conjunctival application of TTd in BALB/c mice induced TTd-specific secretory IgA production and skewed the TTd-specific immune response toward a Th1/Th17 profile, as determined by the stimulation of IFNγ and IL-17A secretion and/or the concurrent pronounced reduction of IL-4 secretion, irrespective of the adjuvant. In conjunctivaly immunized C57BL/6 mice, only TTd administered with wBP promoted the establishment of a mixed Th1/Th17 TTd-specific immune response, whereas TTd alone or TTd in conjunction with glycerol initiated a dominant Th1 response against TTd. Immunization via the conjunctiva with TTd plus wBP adjuvant resulted in a 33% survival rate of challenged mice compared to a 0% survival rate in non-immunized animals (p<0.05).

Conclusion: Conjunctival immunization with TTd alone or with various adjuvants induced TTd-specific local and systemic immune responses, predominantly of the Th1 type. The strongest immune responses developed in mice that received TTd together with wBP, which implies that this alternative route might tailor the immune response to fight intracellular bacteria or viruses more effectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Bacterial / blood
  • Antibodies, Bacterial / immunology
  • Antibody Formation / drug effects
  • Antibody Formation / immunology
  • Antigens, Bacterial / immunology*
  • B-Lymphocytes / cytology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Bordetella pertussis / immunology
  • Cell Proliferation / drug effects
  • Conjunctiva / immunology*
  • Conjunctiva / pathology
  • Cytokines / metabolism
  • Female
  • Immunity, Mucosal / drug effects
  • Immunity, Mucosal / immunology*
  • Immunization*
  • Immunoglobulin A, Secretory / blood
  • Immunoglobulin A, Secretory / metabolism
  • Immunoglobulin G / blood
  • Lymph Nodes / cytology
  • Lymph Nodes / drug effects
  • Lymph Nodes / immunology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Subcutaneous Tissue / drug effects
  • Subcutaneous Tissue / immunology
  • Submandibular Gland / cytology
  • Tears / immunology
  • Tetanus Toxin / toxicity
  • Tetanus Toxoid / immunology*
  • Th1 Cells / cytology
  • Th1 Cells / drug effects
  • Th1 Cells / immunology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Cytokines
  • Immunoglobulin A, Secretory
  • Immunoglobulin G
  • Tetanus Toxin
  • Tetanus Toxoid

Grants and funding

This research was funded by the Laura Bassi Centers of Expertise (FFG Project Number: 822768, http://www.ffg.at/en) and the Republic of Austria and was partly supported by the Ministry of Education, Science, and Technological Development of the Republic of Serbia (Grant Number 172049, http://www.mpn.gov.rs/sajt/index.php?page=1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.